EPRX Reports 36-Week Tissue Health & Symptom Data from Highest Dose Cohort in RESOLVE Trial, 66% Clinical Remission, 90% Tissue Health Reduction, No SAEs, 230+ Patient-Months Follow-Up
Eupraxia Pharmaceuticals Inc. Common Stock · Now $6.86
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS